当前位置:首页 - 行情中心 - 川宁生物(301301) - 财务分析 - 现金流量表

川宁生物

(301301)

  

流通市值:67.96亿  总市值:245.31亿
流通股本:6.18亿   总股本:22.30亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,617,175,171.52620,005,079.474,653,467,257.763,108,948,836.09
  收到的税费返还-020,662,248.911,185,342.77
  收到其他与经营活动有关的现金35,719,213.0428,158,410.87108,982,515.7255,526,536.86
  经营活动现金流入小计1,652,894,384.56648,163,490.344,783,112,022.393,165,660,715.72
  购买商品、接受劳务支付的现金623,684,186.24199,143,610.831,688,602,393.041,374,076,632.27
  支付给职工以及为职工支付的现金266,613,711.34159,333,188.58487,314,482.1338,659,024.58
  支付的各项税费346,751,292.02167,563,156.57669,136,122.55572,306,170.75
  支付其他与经营活动有关的现金24,361,426.565,538,993.84146,991,748.355,359,218.68
  经营活动现金流出小计1,261,410,616.16531,578,949.822,992,044,746.042,290,401,046.28
  经营活动产生的现金流量净额391,483,768.4116,584,540.521,791,067,276.35875,259,669.44
二、投资活动产生的现金流量:
  收回投资收到的现金960,449,358.05200,464,358.91205,506,853.08200,000,000
  取得投资收益收到的现金1,115,193.43-631,1001,145,426.03
  处置固定资产、无形资产和其他长期资产收回的现金净额--46,180.51-
  投资活动现金流入小计961,564,551.48200,464,358.91206,184,133.59201,145,426.03
  购建固定资产、无形资产和其他长期资产支付的现金24,203,403.7410,215,903.2942,601,377.7877,828,060.13
  投资支付的现金982,360,666.67412,750,000269,800,000234,800,000
  投资活动现金流出小计1,006,564,070.41422,965,903.29312,401,377.78312,628,060.13
  投资活动产生的现金流量净额-44,999,518.93-222,501,544.38-106,217,244.19-111,482,634.1
三、筹资活动产生的现金流量:
  吸收投资收到的现金12,935,520-26,191,92026,191,920
  其中:子公司吸收少数股东投资收到的现金--5,931,0005,931,000
  取得借款收到的现金--780,000,000690,000,000
  筹资活动现金流入小计12,935,5200806,191,920716,191,920
  偿还债务支付的现金25,333,33322,333,3331,561,333,3331,023,333,333
  分配股利、利润或偿付利息支付的现金613,781,953.066,418,022.04545,072,524.74536,133,748.42
  支付其他与筹资活动有关的现金577,615.2-60,855,230.460,855,230.4
  筹资活动现金流出小计639,692,901.2628,751,355.042,167,261,088.141,620,322,311.82
  筹资活动产生的现金流量净额-626,757,381.26-28,751,355.04-1,361,069,168.14-904,130,391.82
四、汇率变动对现金及现金等价物的影响3,203,527.391,905,343.16,537,247.241,255,140.02
五、现金及现金等价物净增加额-277,069,604.4-132,763,015.8330,318,111.26-139,098,216.46
  加:期初现金及现金等价物余额1,085,404,379.061,085,404,379.06758,013,563.35758,013,563.35
  期末现金及现金等价物余额808,334,774.66952,641,363.261,088,331,674.61618,915,346.89
补充资料:
  净利润454,575,661.01-1,400,350,219.97-
  资产减值准备29,236,268.77-10,387,988.59-
  固定资产和投资性房地产折旧273,102,983.68-519,591,217.3-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧273,102,983.68-519,591,217.3-
  无形资产摊销9,732,525.89-22,151,665.61-
  长期待摊费用摊销439,126.5-878,253-
  处置固定资产、无形资产和其他长期资产的损失-352,143.38---
  固定资产报废损失859,508.76-1,247,122.82-
  公允价值变动损失-4,354.45--31,500-
  财务费用18,204,971.56-55,373,012.79-
  投资损失-501,508.54--358,468.07-
  递延所得税-2,940,164.75-460,728.5-
  其中:递延所得税资产减少-3,026,396.23-768,004.49-
    递延所得税负债增加86,231.48--307,275.99-
  存货的减少219,184,289.14-317,295,353.6-
  经营性应收项目的减少-434,368,262.14--557,510,093.81-
  经营性应付项目的增加-184,487,916.05--7,987,519.08-
  其他--12,494,626.76-
  不涉及现金收支的投资和筹资活动金额其他项目--311,206,323.31-
  现金的期末余额808,334,774.66-1,088,331,674.61-
  减:现金的期初余额1,085,404,379.06-758,013,563.35-
  现金及现金等价物的净增加额-277,069,604.4-330,318,111.26-
公告日期2025-08-262025-04-292025-04-222024-10-22
审计意见(境内)标准无保留意见
TOP↑